Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- rosuvastatin
- vemurafenib
Interactions between your drugs
rosuvastatin vemurafenib
Applies to: rosuvastatin, vemurafenib
MONITOR: Coadministration with vemurafenib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) transporters, such as dabigatran, rosuvastatin, sulfasazine, and topotecan. The proposed mechanism, based on in vitro data, is decreased clearance due to vemurafenib-mediated inhibition of P-gp and/or BCRP efflux transport proteins.
MANAGEMENT: Caution is advised if vemurafenib is used concomitantly with drugs that are substrates of P-gp and/or BCRP transport proteins, particularly those with a narrow therapeutic range. Some authorities suggest avoiding the use of vemurafenib with drugs that are substrates of these transport proteins and have a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever vemurafenib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.
References (3)
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Cerner Multum, Inc. "Australian Product Information."
- (2011) "Product Information. Zelboraf (vemurafenib)." Genentech
Drug and food/lifestyle interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Lipitor
Lipitor is used to treat high cholesterol. Learn about side effects, interactions and indications.
Crestor
Crestor (rosuvastatin) is used to treat high cholesterol and high triglycerides in the blood ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Zetia
Zetia (ezetimibe) is used to treat high cholesterol. Includes Zetia side effects, interactions and ...
Zocor
Zocor (simvastatin) reduces low-density lipoprotein cholesterol and total cholesterol in the blood ...
Mevacor
Mevacor is used for high cholesterol, high cholesterol, familial heterozygous ...
Colesevelam
Colesevelam is used for diarrhea, chronic, high cholesterol, hyperlipoproteinemia ...
Niacin
Niacin is used to lower cholesterol and triglycerides. Learn about side effects, interactions and ...
Lovastatin
Lovastatin is used for high cholesterol, high cholesterol, familial heterozygous ...
Simvastatin
Simvastatin (Zocor) is a cholesterol-lowering medication that blocks the production of cholesterol ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.